title: Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
abstract: BACKGROUND
  Ketanserin is a serotonin S2-receptor antagonist that inhibits the platelet activation and vasoconstriction induced by serotonin and also inhibits the mitogenic effect of serotonin on vascular smooth muscle cells.
  
  
  RESULTS
  We conducted a randomized, double blind, placebo-controlled trial to assess the effect of ketanserin in restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA). Patients received either ketanserin (loading dose, 40 mg 1 hour before PTCA; maintenance dose, 40 mg bid for 6 months) or matched placebo. In addition, all patients received aspirin for 6 months. Coronary angiograms before PTCA, after PTCA, and at 6 months were quantitatively analyzed. Six hundred fifty-eight patients were entered into the intention-to-treat analysis. The primary clinical end point of the study was the occurrence between PTCA and 6 months of any one of the following: cardiac death, myocardial infarction, the need for repeat angioplasty, or bypass surgery. It also included the need for revascularization actuated by findings at 6-month follow-up angiography. The primary clinical end point was reached by 92 (28%) patients in the ketanserin group and 104 (32%) in the placebo group (RR, 0.89; 95% CI, 0.70, 1.13; P = .38). Quantitative angiography after PTCA and at follow-up was available in 592 patients (ketanserin, 287; control, 305). The mean difference in minimal lumen diameter between post-PTCA and follow-up angiogram (primary angiographic end point) was 0.27 +/- 0.49 mm in the ketanserin group and 0.24 +/- 0.52 mm in the control group (difference, 0.03 mm; 95% CI, -0.05, 0.11; P = .50).
  
  
  CONCLUSIONS
  Ketanserin at the dose administered in this trial failed to reduce the loss in minimal lumen diameter during follow-up after PTCA and did not significantly improve the clinical outcome.
authors.affiliation: Catheterization Laboratory, Thoraxcenter, Rotterdam, The Netherlands.
authors.forename: P W
authors.initials: PW
authors.lastname: Serruys
authors.forename: W
authors.initials: W
authors.lastname: Klein
authors.forename: J P
authors.initials: JP
authors.lastname: Tijssen
authors.forename: W
authors.initials: W
authors.lastname: Rutsch
authors.forename: G R
authors.initials: GR
authors.lastname: Heyndrickx
authors.forename: H
authors.initials: H
authors.lastname: Emanuelsson
authors.forename: S G
authors.initials: SG
authors.lastname: Ball
authors.forename: O
authors.initials: O
authors.lastname: Decoster
authors.forename: E
authors.initials: E
authors.lastname: Schroeder
authors.forename: H
authors.initials: H
authors.lastname: Liberman
mesh_terms: D000328:Adult; D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000517:prevention & control / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007650:Ketanserin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D007650:Ketanserin